MALVERN, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD).  "The completion of the Alzheimer's study marks a significant step in our efforts to bring new therapies to patients," said Maria Maccecchini, Ph.D., Founder, President, and CEO ...